Adverum Biotechnologies Inc
NASDAQ:ADVM

  • LAST PRICE
    7.7200
  • TODAY'S CHANGE (%)
    0.1800 (2.3873%)
  • Bid / Lots
    7.2500/ 1
  • Ask / Lots
    8.1500/ 30
  • Open / Previous Close
    7.5300 / 7.5400
  • Day Range
    7.2600
    7.7672
  • 52 Week Range
    6.3800
    29.7000
  • Volume
    104,776

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

  • Yesterday

  • Oct 16, 2024

      Show headlines and story abstract

    • 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
      Companies Mentioned: ADVM

      Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

      REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE(R) in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injection for the treatment of neovascular or wet age-related macular degeneration (wet AMD). Ixo-vec is currently being evaluated in the Phase 2 LUNA clinical trial. The company plans to announce LUNA 52-week data and pivotal program details in the 4(th) quarter of 2024. In addition, the company is on track to initiate the Ixo-vec pivotal program in the 1(st) half of 2025.

Peers Headlines